All In Biotech

Drug Trial Radar · NCT07363265

Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease

A Multicenter, Open-label Phase Ⅱ Study to Evaluate the Efficacy and Safety of LP-005 Injection in Patients With Complement-Mediated Kidney Disease

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Feb 2, 2026

Primary completion

Aug 2, 2028

Study completion May 2, 2029

Sponsor

Lead sponsor
Longbio PharmaIndustry
Sponsor type
Industry
First posted
Jan 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, proof-of-concept, phase Ⅱ adaptive basket clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of LP-005 Injection as add-on therapy to standard treatment in patients with complement-mediated renal diseases.

Conditions

  • Complement-mediated Renal Diseases

Interventions

  • LP-005 InjectionBiological

    IV, Q4W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in 24-hour urinary protein-to-creatinine ratio (UPCR) in Basket 1 cohortTime frame: Week 24
  2. Proportion of patients with a ≥25% reduction in serum creatinine (SCr) from baseline in Basket 2 cohortTime frame: Week 24
  3. Proportion of patients without dialysis requirement in Basket 3 cohortTime frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.